NasdaqGM - Nasdaq Real Time Price USD

RxSight, Inc. (RXST)

Compare
49.57 +1.06 (+2.19%)
At close: 4:00 PM EDT
49.00 -0.57 (-1.15%)
After hours: 5:07 PM EDT
Loading Chart for RXST
DELL
  • Previous Close 48.51
  • Open 48.85
  • Bid --
  • Ask --
  • Day's Range 48.85 - 50.24
  • 52 Week Range 20.66 - 66.54
  • Volume 233,458
  • Avg. Volume 480,476
  • Market Cap (intraday) 1.967B
  • Beta (5Y Monthly) 1.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.99
  • Earnings Date Nov 7, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 64.86

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

www.rxsight.com

374

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RXST

View More

Performance Overview: RXST

Trailing total returns as of 10/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RXST
22.94%
S&P 500
21.80%

1-Year Return

RXST
106.54%
S&P 500
37.77%

3-Year Return

RXST
322.59%
S&P 500
27.83%

5-Year Return

RXST
183.26%
S&P 500
32.18%

Compare To: RXST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RXST

View More

Valuation Measures

Annual
As of 10/23/2024
  • Market Cap

    1.93B

  • Enterprise Value

    1.70B

  • Trailing P/E

    --

  • Forward P/E

    105.26

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    15.47

  • Price/Book (mrq)

    6.99

  • Enterprise Value/Revenue

    14.79

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.93%

  • Return on Assets (ttm)

    -10.58%

  • Return on Equity (ttm)

    -17.01%

  • Revenue (ttm)

    115.18M

  • Net Income Avi to Common (ttm)

    -36.77M

  • Diluted EPS (ttm)

    -0.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    233.28M

  • Total Debt/Equity (mrq)

    4.15%

  • Levered Free Cash Flow (ttm)

    -19.18M

Research Analysis: RXST

View More

Company Insights: RXST

Research Reports: RXST

View More

People Also Watch